Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Madison, Wisconsin 53792


The purpose of this study is to determine if reduction in premature ventricular contraction (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma catecholamines and an improvement in baroreflex gain. Flecainide will be used for PVC suppression in a randomized, double-blinded, crossover fashion.


Inclusion Criteria: - Frequent symptomatic premature ventricular contractions (PVCs) (>10% of total QRSs on a 24-hour Holter) - Willingness to participate in research Exclusion Criteria: - Age > 65 years old - Pacemaker implantation - Implantable cardioverter defibrillator implantation requiring pacing - Sick sinus syndrome - Atrio-ventricular (AV) block - Left ventricular dysfunction defined as left ventricular ejection fraction < 50% - History of myocardial infarction or coronary artery disease - Severe left ventricular hypertrophy (wall thickness > 1.5 cm by echocardiography performed within 3 months from enrollment) - Severe liver dysfunction - Creatinine clearance of 35 mL/min/1.73 square meters or less - Pregnancy - Known hypersensitivity to the drug - QRS duration > 120 ms - Recent change in blood pressure medication within 30 days of enrollment



Primary Contact:

Principal Investigator
Mohamed H Hamdan, MD, MBA
University of Wisconsin, Madison

Backup Contact:


Location Contact:

Madison, Wisconsin 53792
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.